Fig. 1.
The roles of spinal interleukin (IL)-33 and its receptor ST2 in spared nerve injury (SNI)-induced neuropathic pain. (A and B) Time course of the changes in paw-withdrawal thresholds in the von Frey test and the durations of lifting/licking in the acetone test after SNI. *P < 0.05, **P < 0.001 compared with the naive group; n = 11 mice for each group. BS = Baseline. (C and D) Dose-dependent effects of the intrathecal administration of the ST2 antibody on the paw-withdrawal thresholds and on the durations of lifting/licking on the 7th day after SNI. *P < 0.05, **P < 0.01 compared with the IgG group; n = 12 mice for each group. (E and F) The effects of repeated intrathecal administrations of the ST2 antibody on the mechanical (E) and cold (F) allodynia changes after SNI. The ST2-neutralizing antibody (300 ng) was administrated once daily for 6 continuous days from the 3rd day to the 8th day after SNI. *P < 0.05, **P < 0.01 compared with the IgG group; n = 6 mice for each group. (G and H) The time courses of the changes in the paw-withdrawal thresholds and the durations of lifting/licking after SNI in the wild-type (WT) and ST2 gene knockout (ST2−/−) mice. *P < 0.05, **P < 0.001 compared with the WT naive group. #P < 0.01 compared with the WT SNI group; n = 10 to 12 mice for each group. (I and J) The effects of intrathecal administration recombinant IL-33 (rIL-33) on the paw-withdrawal thresholds and durations of lifting/licking in the naive mice. *P < 0.05, **P < 0.01 compared with the phosphate buffer solution (PBS) group; n = 8 mice for each group. (K and L) The inhibitory effects of intrathecal administration of rIL-33 (90 ng) on the induced nociceptive behaviors of the ST2−/− naive mice. **P < 0.01 compared with the PBS WT group. #P < 0.01 compared with the rIL-33 WT group; n = 8 mice for each group. All data are shown as the mean ± SEM.

The roles of spinal interleukin (IL)-33 and its receptor ST2 in spared nerve injury (SNI)-induced neuropathic pain. (A and B) Time course of the changes in paw-withdrawal thresholds in the von Frey test and the durations of lifting/licking in the acetone test after SNI. *P < 0.05, **P < 0.001 compared with the naive group; n = 11 mice for each group. BS = Baseline. (C and D) Dose-dependent effects of the intrathecal administration of the ST2 antibody on the paw-withdrawal thresholds and on the durations of lifting/licking on the 7th day after SNI. *P < 0.05, **P < 0.01 compared with the IgG group; n = 12 mice for each group. (E and F) The effects of repeated intrathecal administrations of the ST2 antibody on the mechanical (E) and cold (F) allodynia changes after SNI. The ST2-neutralizing antibody (300 ng) was administrated once daily for 6 continuous days from the 3rd day to the 8th day after SNI. *P < 0.05, **P < 0.01 compared with the IgG group; n = 6 mice for each group. (G and H) The time courses of the changes in the paw-withdrawal thresholds and the durations of lifting/licking after SNI in the wild-type (WT) and ST2 gene knockout (ST2−/−) mice. *P < 0.05, **P < 0.001 compared with the WT naive group. #P < 0.01 compared with the WT SNI group; n = 10 to 12 mice for each group. (I and J) The effects of intrathecal administration recombinant IL-33 (rIL-33) on the paw-withdrawal thresholds and durations of lifting/licking in the naive mice. *P < 0.05, **P < 0.01 compared with the phosphate buffer solution (PBS) group; n = 8 mice for each group. (K and L) The inhibitory effects of intrathecal administration of rIL-33 (90 ng) on the induced nociceptive behaviors of the ST2−/− naive mice. **P < 0.01 compared with the PBS WT group. #P < 0.01 compared with the rIL-33 WT group; n = 8 mice for each group. All data are shown as the mean ± SEM.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal